Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Male or female patient ≥ 18 years of age~* Classification of Sjögren's Syndrome according to ACR/EULAR 2016 criteria (Shiboski et al 2017)~* Seropositive for anti-Ro/SSA antibodies~* Stimulated whole salivary flow rate of ≥ 0.1 mL/min~Inclusion criteria specific for Cohort 1:~* ESSDAI ≥ 5 within the 8 predefined organ domains~* ESSPRI score of ≥5~Inclusion criteria specific for Cohort 2:~* ESSDAI \< 5 within 8 domains scored for inclusion criterion for Cohort 1~* ESSPRI fatigue subscore ≥ 5 or ESSPRI dryness subscore ≥ 5~Exclusion Criteria:~* Sjögren's Syndrome overlap syndromes where another autoimmune rheumatic disease constitutes the principle illness~* Use of other investigational drugs~* Prior use of B cell depleting therapies, abatacept or any other immunosuppressants unless specifically allowed be the protocol.~* Use of steroids at dose \>10 mg/day.~* Uncontrolled ocular rosacea (affecting the eye adnexa), posterior blepharitis or Meibomian gland disease (this criterion applies only to patients considered for Cohort 2)~* Active viral, bacterial or other infections requiring systemic treatment~* Receipt of live/attenuated vaccine within a 2-month period prior to randomization.~* Chronic infection with hepatitis B (HBV) or hepatitis C (HCV).~* Evidence of active tuberculosis (TB) infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 /Arm A (Type: EXPERIMENTAL): CFZ533 dose 1
- Cohort 1/Arm B (Type: EXPERIMENTAL): CFZ533 dose 2
- Cohort 1/Arm C (Type: EXPERIMENTAL): CFZ533 dose 3
- Cohort 1/Arm D (Type: PLACEBO_COMPARATOR): Placebo dose (up to week 24)
- Cohort 1/Arm D1 (Type: EXPERIMENTAL): CFZ533 dose 1 (from week 24)
- Cohort 2/Arm E (Type: EXPERIMENTAL): CFZ533 dose 1
- Cohort 2/Arm F (Type: PLACEBO_COMPARATOR): Placebo dose (up to week 24)
- Cohort 2/Arm F1 (Type: EXPERIMENTAL): CFZ533 dose 2 (from week 24)

Based on this trial design, predict the completion outcome and termination type (if applicable).